Physician profile
Brian K Knighton
NPI 1700824000
$28,998.56
in general payments reported to CMS, 2019-2025
61 companies · $3,986 in 2025
The $3,986 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,311 · 2020: $2,377 · 2021: $3,746 · 2022: $4,484 · 2023: $5,147 · 2024: $5,948 · 2025: $3,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $0.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,080.10 |
| Education | $0.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,377.90 | 2019-2025 | |
| Novo Nordisk INC | $2,938.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,819.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $2,718.85 | 2019-2025 | |
| Amgen INC. | $1,794.05 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,591.88 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,514.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,242.16 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $976.44 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $922.33 | 2019-2025 | Gardasil 9, Verquvo, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $859.62 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $688.12 | 2021-2025 | |
| Daiichi Sankyo INC. | $512.20 | 2023-2024 | Injectafer |
| Lundbeck LLC | $508.25 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $417.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Knighton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.